Alfuzosin for Benign Prostatic Hyperplasia
Dosing and Administration
Alfuzosin should be dosed at 10 mg once daily, taken immediately after the same meal each day 1. The tablet must be swallowed whole and never crushed, chewed, or split 1. Taking alfuzosin on an empty stomach reduces absorption by 50%, making food intake essential for therapeutic efficacy 1. The extended-release formulation achieves peak plasma concentrations at 8 hours and reaches steady-state by the second dose 1.
No dose titration is required—patients start at the therapeutic dose of 10 mg daily 1, 2. This represents a significant practical advantage over older alpha-blockers like terazosin or doxazosin that require gradual titration.
Contraindications
Alfuzosin is absolutely contraindicated in three situations 1:
- Moderate to severe hepatic impairment (Child-Pugh B or C) due to significantly elevated drug levels
- Concurrent use with potent CYP3A4 inhibitors including ketoconazole, itraconazole, and ritonavir
- Known hypersensitivity to alfuzosin or tablet components
The drug is also not indicated for women, children, or treatment of hypertension 1.
Critical Precautions
Cardiovascular Considerations
While alfuzosin demonstrates uroselective properties with minimal vasodilatory effects compared to older alpha-blockers 3, patients with uncontrolled or untreated hypertension may experience significant blood pressure reductions 4. In a multicenter study, alfuzosin decreased both systolic and diastolic BP in hypertensive patients, whether used alone or combined with antihypertensive medications 4. Warn these patients about potential hypotension at therapy initiation.
Patients with a history of syncope, dizziness, or orthostatic hypotension require counseling about these risks 1.
QT Interval Effects
Alfuzosin at therapeutic doses (10 mg) produces minimal QT prolongation (mean QTcF increase of 1.9 msec) 1. However, at supratherapeutic doses (40 mg), the effect increases to 7.7 msec 1. While no cases of Torsades de Pointes have been reported in extensive post-marketing surveillance, exercise caution when combining with other QT-prolonging medications.
Ophthalmic Surgery
Inform ophthalmologists before cataract surgery if the patient is taking or has previously taken alfuzosin, as alpha-blockers are associated with intraoperative floppy iris syndrome 3, 1. This complication can occur even after discontinuation of the medication.
Renal Impairment
Unlike hepatic impairment, renal dysfunction does not require dose adjustment, as it does not significantly alter alfuzosin pharmacokinetics 2.
Drug Interactions
Beyond the absolute contraindication with potent CYP3A4 inhibitors, moderate CYP3A4 inhibitors (diltiazem, cimetidine) and other medications (atenolol) can elevate alfuzosin levels 2. Monitor for enhanced pharmacodynamic effects including increased dizziness or hypotension when combining these agents.
Efficacy Profile
Alpha-blockers including alfuzosin are first-line medical therapy for BPH/LUTS 3. Alfuzosin demonstrates equivalent efficacy to other alpha-blockers when dosed appropriately 5. In clinical trials, alfuzosin reduced IPSS scores by approximately 55% and increased maximum flow rate (Qmax) by 53% over 3 months 6. The 2023 EAU guidelines support alpha-blocker monotherapy as initial management for moderate-to-severe LUTS 3.
Notably, alfuzosin does not reduce prostate volume—it works purely through dynamic (smooth muscle relaxation) rather than static mechanisms 3.
Acute Urinary Retention
For patients presenting with acute urinary retention (AUR) related to BPH, prescribe alfuzosin prior to trial without catheter (TWOC) 7. Patients should complete at least 3 days of alpha-blocker therapy before attempting catheter removal 7. Pooled data shows alfuzosin achieves successful TWOC in 60% of patients versus 39% with placebo 7. However, counsel patients that they remain at increased risk for recurrent retention even after successful TWOC 7.
Common Adverse Effects
The most frequent side effects include dizziness, headache, and fatigue 1. Sexual dysfunction, particularly ejaculatory disorders, occurs at lower rates with alfuzosin compared to other alpha-blockers due to its uroselective properties 8. One study demonstrated improvement rather than deterioration in IIEF scores (11.98-19.7% improvement across sexual function domains) during alfuzosin therapy 6.
Storage
Store between 59-86°F (15-30°C), protected from light and moisture 1.